JAG1 (Jagged 1) is a canonical Notch ligand that activates Notch signaling. JAG1 is crucial for development of the heart, vasculature, and inner ear. In the nervous system, JAG1-Notch signaling regulates neural stem cell maintenance, neuronal differentiation, and angiogenesis. JAG1 mutations cause Alagille syndrome and have been linked to neurodevelopmental disorders.
| Protein Name | JAG1 (Jagged 1) |
|---|
| Gene | [JAG1](/genes/jag1) |
|---|
| UniProt ID | [P78504](https://www.uniprot.org/uniprot/P78504) |
|---|
| PDB Structures | 3WJP, 4XDX |
|---|
| Molecular Weight | ~134 kDa |
|---|
| Subcellular Localization | Plasma membrane |
|---|
| Protein Family | Notch ligand (Jagged family) |
|---|
JAG1 is a type I transmembrane protein :
- Extracellular domain (1-1064 aa): Contains 16 EGF-like repeats and DSL domain
- DSL domain (192-240 aa): Required for Notch binding - the name derives from Drosophila Delta, Serrate, and Lag-1
- Cysteine-rich region: Unique to the Jagged family - not present in Delta ligands
- Transmembrane domain (1065-1087 aa): Single-pass anchor
- Intracellular domain (1088-1218 aa): PDZ-binding motif for protein interactions
EGF-like repeats (1-16): Each contains 6 conserved cysteine residues forming three disulfide bonds, creating a rigid structural motif important for protein-protein interactions.
DSL domain: The critical Notch-binding interface. Mutagenesis studies show key residues in this region are essential for Notch activation.
Cysteine-rich region: Unique to Jagged ligands, contains multiple cysteine residues that form disulfide bonds. This region may influence signaling kinetics and receptor selectivity.
Unlike DLL1, JAG1 shows slower kinetics in Notch activation, resulting in different biological outcomes.
JAG1 mediates diverse Notch-dependent processes:
- Neurogenesis: Maintains neural progenitor cells in proliferative state
- Gliogenesis: Promotes astrocyte differentiation
- Axon guidance: Directs growth cone decisions
- Synapse formation: Regulates postsynaptic differentiation
- Arterial specification: Critical for arterial identity
- Vascular development: Promotes blood vessel formation
- Tip cell selection: Guides sprouting angiogenesis
- Stem cell maintenance: Supports hematopoietic stem cell niches
- T cell development: Thymic T cell differentiation
- Myeloid differentiation: Influences myeloid lineage decisions
- Heart development: Valve formation
- Inner ear: Hair cell development
- Liver: Bile duct formation
JAG1-Notch signaling follows a canonical path :
- JAG1 expression and processing: JAG1 is synthesized and undergoes furin-mediated cleavage in the Golgi
- Membrane presentation: Processed JAG1 is presented on the cell surface
- Notch receptor binding: JAG1 binds to Notch receptors (NOTCH1-4)
- Notch cleavage (S1): Furin cleavage produces heterodimeric receptor
- S2 cleavage: ADAM/TACE proteases cleave Notch extracellular domain
- S3 cleavage: γ-secretase releases Notch intracellular domain (NICD)
- Nuclear translocation: NICD enters nucleus
- Transcriptional activation: NICD forms complex with CSL and co-activators
- Target gene expression: Hes, Hey, and other Notch target genes are transcribed
JAG1 can signal through non-canonical routes :
- β-catenin activation: JAG1 can activate Wnt/β-catenin pathway
- NF-κB signaling: JAG1 can influence inflammatory responses
- mTOR pathway: JAG1 affects cell growth and metabolism
JAG1-Notch intersects with multiple signaling networks:
- Wnt/β-catenin: Reciprocal regulation
- Hedgehog: Cross-talk in neural progenitors
- FGF signaling: Coordinate patterning
- BMP pathway: Integrate morphogen signals
Neural stem cells (NSCs):
- High JAG1 expression in ventricular zone
- Maintains NSC proliferation
- Regulates fate decisions
Neurons:
- Expression in specific neuronal populations
- Activity-dependent regulation
- Synaptic localization
Astrocytes:
- JAG1 in reactive astrocytes
- Contributes to neuroinflammation
- Gliotic response modulation
Endothelial cells:
High JAG1 expression in:
- Subventricular zone (SVZ): NSC niche
- Hippocampus: CA1, CA3 regions
- Cerebral cortex: Layer-specific patterns
- Cerebellum: Purkinje cell layer
Lower expression in:
- White matter tracts
- Mature neuronal layers
JAG1 is altered in AD and contributes to pathogenesis :
Expression changes:
- JAG1 expression altered in AD brains
- Increased JAG1 in vicinity of amyloid plaques
- Changes in Notch-JAG1 axis
Pathogenic mechanisms:
- Impacts neural stem cell niches - reduces neurogenesis
- May influence amyloid processing and clearance
- Notch-JAG1 in inflammatory responses - promotes microglial activation
- Affects tau pathology through Notch interactions
Therapeutic implications:
- Targeting JAG1-Notch axis
- Modulating neuroinflammation
- Enhancing neurogenesis
In PD, JAG1 affects:
Dopaminergic neurons:
- Expressed in dopaminergic regions
- May affect neuronal survival
- Influences vulnerability
Neuroinflammation:
- Implicated in neuroinflammation
- Microglial Notch activation
- Chronic inflammatory responses
Therapeutic potential:
- Notch inhibitors under investigation
- Anti-inflammatory approaches
¶ Stroke and CNS Injury
Following stroke and brain injury:
- Role in post-ischemic angiogenesis
- Mediates inflammatory responses
- Neural stem cell response to injury
- Potential for vascular repair
- Alagille syndrome: JAG1 mutations cause this syndrome with neurological manifestations
- Developmental delays: Associated with JAG1 mutations
- Seizures: Can be associated with JAG1 variants
1. Notch inhibitors:
- Gamma-secretase inhibitors: Block S3 cleavage
- DLL-based decoys: Soluble Notch competitors
- Antibody-based blockade
2. JAG1-specific approaches:
- Anti-JAG1 antibodies: Block ligand-receptor interaction
- Small molecule modulators: In development
- RNA-based approaches: siRNA, antisense
3. Downstream effectors:
- γ-secretase inhibitors
- CSL inhibitors
- NICD stabilizers/destabilizers
- Broad Notch inhibition has side effects
- Tissue-specific targeting needed
- Timing critical for efficacy
- Balance between beneficial and detrimental effects
¶ Genetics and Variants
JAG1 mutations cause:
- Alagille syndrome: Autosomal dominant, ~1 in 70,000 births
- Tetralogy of Fallot: Associated with JAG1 variants
- Neurodevelopmental disorders: Rare variants
JAG1 variants associated with:
- Psychiatric disorders
- Neurological phenotypes
- Response to therapy
- Immunohistochemistry: JAG1 protein in brain tissue
- In situ hybridization: mRNA distribution
- Flow cytometry: Surface expression
- Western blot: Protein levels
- RNA-seq: Transcriptome analysis
- In vitro: Neural stem cells, neurons, endothelial cells
- In vivo: Mouse models, zebrafish
- Human: Post-mortem tissue, iPSC-derived cells
- CRISPR/Cas9 editing
- siRNA/shRNA knockdown
- Overexpression studies
- Reporter assays